TrueTicker

NIFTY 500 › Healthcare

Healthcare · NIFTY 500

Narayana Hrudayalaya Ltd.

NH on NSE · 19 Nov 2026

NIFTY 500

1,873.10 ▼ -0.96 % on the day

Overview Technical Risk & rank Quality Results Accounts Filings Guidance & governance

Filings

52 filings of NH since November 2024; the newest 40 below.

presentation 14, board outcome 12, transcript 9, scheme 5, results 5, credit rating 3

FiledTypeSubject
07 Nov 2026transcript
Capex, Guidance, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of Earnings Call for the quarter and half year ended September 30, 2026.
AI summary

Narayana Hrudayalaya Limited filed the transcript of its Q2 FY27 earnings call held on November 02, 2026 for the quarter and half year ended September 30, 2026.

On the India business, management said IP volumes rose 4% year-on-year, OP footfall rose about 12.5%, and ARPOB rose from INR17.5 million to INR19.5 million (annualised); Venkatesh said margins went above 26%.

Viren Shetty said the company does not target specific margins and wants volume growth; Sandhya Jayaraman said IP footfalls grew 6% quarter-on-quarter and almost 4% year-on-year.

On insurance, Nishant Singh said the combined loss of the two businesses was about INR33 crores last quarter and INR22 crores this quarter; management said it is too early to give a break-even timeline.

Sandhya Jayaraman said group ROCE is 15% to 16%, with a 5 to 7 year horizon for the UK business.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
04 Nov 2026scheme
Acquisition, Legal
Narayana Hrudayalaya Ltd. has informed the Exchange about Filing of the Orderof the Hon ble National Company Law Tribunal, Bengaluru Bench sanctioning the Scheme ofArrangement between NH Integrated Care Private Limited (WOS) and NarayanaHru
AI summary

Narayana Hrudayalaya Limited filed the NCLT, Bengaluru Bench order sanctioning the Scheme of Arrangement between its wholly owned subsidiary NH Integrated Care Private Limited (demerged company) and the company (resulting company) under Sections 230 to 232 of the Companies Act, 2013.

The order was uploaded on the NCLT website on November 4, 2026; the certified copy is awaited, and the appointed date is April 1, 2025.

The scheme demerges the Clinical Services undertaking of the subsidiary, comprising 9 clinics in Bengaluru and 1 clinic in Hosur, into the company on a going-concern basis.

No shares will be issued as consideration, so there is no change in the company's share capital or shareholding pattern.

The scheme becomes effective on the last date on which the certified copy of the order is filed with the Registrar of Companies; the company will inform the exchanges on effectiveness.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Nov 2026presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Health filed a revised investor presentation for the quarter and half year ended September 30, 2026 (Q2 FY27).

Consolidated operating revenues were ₹28,440 Mn in Q2 FY27, up 73.0% YoY and 6.0% QoQ.

Consolidated EBITDA was ₹6,054 Mn at a margin of 21.3%; consolidated PAT was ₹3,012 Mn at a margin of 10.6%.

Consolidated net debt (borrowings less cash, bank balances and investments) was ₹18,830 Mn as on September 30, 2026, with a net debt to equity ratio of 0.38.

Healthcare facilities total 56 with 6,119 beds as on October 1, 2026, and staff of about 21,150.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Oct 2026presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya Limited filed its investor presentation for the quarter and half year ended September 30, 2026 (Q2 FY27) with BSE and NSE.

Consolidated operating revenues were ₹ 28,440 Mn in Q2 FY27, up 73.0% YoY and 6.0% QoQ; consolidated EBITDA was ₹ 6,054 Mn (margin 21.3%) and consolidated PAT was ₹ 3,012 Mn (margin 10.6%).

Consolidated net debt (total borrowings less cash, bank balances and investments) was ₹ 18,830 Mn as on September 30, 2026, a net debt to equity ratio of 0.38.

As on October 1, 2026, the company had 56 healthcare facilities with 6,119 operational beds and about 21,150 staff.

Management highlighted clinical milestones at its Narayana Institute of Cardiac Sciences, Bengaluru, including South India's first percutaneous transcatheter tricuspid valve replacement and 54 TAVIs in Q2 FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Oct 2026board outcome
Acquisition, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange, the financial results for the quarter and half-year ended September 30, 2026.
AI summary

Board meeting held October 30, 2026 approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, with a limited review report from Deloitte Haskins & Sells LLP.

Standalone revenue from operations for Q2 FY27 (quarter ended Sep 30, 2026) was ₹11,853.77 million, up from ₹10,191.69 million a year earlier; standalone net profit was ₹1,756.26 million versus ₹1,378.80 million.

Standalone net profit for the half year ended Sep 30, 2026 was ₹3,134.81 million, against ₹2,252.51 million in the corresponding period last year; basic EPS for the half year was ₹15.44 (not annualised).

The filing notes the NCLT approval is awaited for the merger of Meridian Medical Research & Hospital Ltd. into the company and for the demerger of clinical services from NH Integrated Care Private Limited, with no impact on the reported results for the period.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
10 Aug 2026transcript
Acquisition, Guidance, Legal, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings call of the company for the quarter ended June 30, 2026.
AI summary

Narayana Hrudayalaya filed the transcript of its Q1 FY27 earnings call held on August 03, 2026, for the quarter ended June 30, 2026.

Management said footfalls and realisations both contributed to India hospital revenue growth, with clinics contributing about 30% of total OPD footfalls and no meaningful bed additions expected for the next two to three years.

Management said the 24% EBITDA margin reflects higher-end procedures, robotics and throughput gains, with margin expansion expected from operating leverage, though no projection was given.

Management acknowledged volatility in the domestic insurance book's loss ratio, attributed to a few large claims in a small book, and said expense ratio fell substantially.

Management said it is too early to measure ROCE on the recently acquired UK business, which may be reported in about four quarters, and gave no definite ROCE target.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Aug 2026presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya filed a revised Investor Presentation for the quarter ended June 30, 2026 (Q1 FY27).

Consolidated operating revenue was ₹26,836 Mn in Q1 FY27, up 78.0% YoY and 3.5% QoQ.

Consolidated EBITDA was ₹5,052 Mn at an 18.8% margin; consolidated PAT was ₹2,073 Mn at a 7.7% margin.

Net debt to equity ratio was 0.42 as on June 30, 2026, with net debt of ₹19,671 Mn.

Operational highlights cited include 2,137 cardiac surgeries at Narayana Institute of Cardiac Sciences, Bengaluru in Q1 FY27, and 6,269 total capacity beds across 55 healthcare facilities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2026presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya Limited filed its Investor Presentation (Earnings Update) for the quarter ended June 30, 2026 (Q1 FY27).

Consolidated operating revenues of ₹26,836 Mn in Q1 FY27, up 78.0% YoY and 3.5% QoQ.

Consolidated EBITDA of ₹5,052 Mn at an 18.8% margin; consolidated PAT of ₹2,073 Mn at a 7.7% margin.

Consolidated net debt (total borrowings less cash, bank balances and investments) of ₹19,671 Mn as on June 30, 2026; net debt to equity ratio of 0.42.

Operational beds total 6,269 across 55 healthcare facilities; 2,137 cardiac surgeries performed at Narayana Institute of Cardiac Sciences, Bengaluru in Q1 FY27.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Jul 2026board outcome
Acquisition, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
AI summary

Board of Narayana Hrudayalaya Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 on July 31, 2026, with an unmodified limited review report from Deloitte Haskins & Sells LLP.

Standalone revenue from operations for Q1 FY27 was ₹10,971.02 million, up from ₹9,431.41 million in the year-ago quarter (June 30, 2025).

Standalone net profit for the quarter was ₹1,378.55 million, compared with ₹873.71 million a year earlier; basic EPS was ₹6.79 (not annualised), against ₹4.30.

Standalone EBITDA was ₹2,695.35 million, versus ₹1,954.54 million a year earlier. Other income was ₹304.13 million, compared with ₹164.36 million.

Pending NCLT approval: the merger of Meridian Medical Research & Hospital Ltd into the company and the demerger of clinical services from NH Integrated Care Private Limited are awaiting final orders from the National Company Law Tribunal, Bengaluru Bench.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
02 Jul 2026results
Results
The Exchange had sought clarification from Narayana Hrudayalaya Ltd. for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Comp
AI summary

Narayana Hrudayalaya Limited filed on July 1, 2026 a clarification to NSE's email of June 29, 2026 about financial results submitted on May 22, 2026.

The company re-submitted a legible, machine-readable copy of the audited standalone and consolidated results for the quarter and year ended March 31, 2026, and confirmed there is no change in their contents.

The company also submitted a revised standalone XBRL file to address a discrepancy where reserves excluding revaluation reserve were not mentioned.

The filing includes an excerpt of the May 22, 2026 board outcome, which recommended a final dividend of Rs. 4.50 per share, with a record date of July 17, 2026 and AGM on August 14, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
29 Jun 2026resultsThe Exchange has sought clarification from Narayana Hrudayalaya Ltd. for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Comp
02 Jun 2026transcript
Acquisition, Guidance, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings call of the company for the quarter and financial year ended March 31, 2026.
AI summary

Narayana Hrudayalaya filed the transcript of its Q4 and FY26 earnings call held on May 26, 2026, and said the transcript is also on its website.

On the India clinics and insurance business, management said losses of about INR 66 crore in FY26 reflect new clinics taking around 18 months to turn around and corporate overheads; management said it cannot give a date for when insurance losses will subside.

Management said it does not give margin guidance, and that ARPOB growth has been healthy, with rack-rate and price increases in the low to mid-single digits year-on-year.

Management said it is not planning to enter the UK insurance business and that the UK acquisition's value case rests on raising private-pay share and lowering cost via its technology platform.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Investor presentation for the quarter and financial year ended March 31, 2026, filed by Narayana Hrudayalaya Limited.

Consolidated operating revenue was ₹25,938 Mn in Q4 FY26 (+75.8% YoY, +20.6% QoQ) and ₹78,960 Mn in FY26 (+44.0% YoY).

Consolidated EBITDA was ₹5,392 Mn in Q4 FY26 (20.8% margin) and ₹17,169 Mn in FY26 (21.7% margin).

Consolidated PAT was ₹2,280 Mn in Q4 FY26 (8.8% margin) and ₹8,105 Mn in FY26 (10.3% margin).

Consolidated net debt was ₹22,397 Mn as on March 31, 2026, with a net debt to equity ratio of 0.49.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026dividend
Dividend / buy-back, Legal, Management change, Results
Narayana Hrudayalaya Ltd. has informed the Exchange that Board of Directors at its meeting held on May 22, 2026, recommended Final Dividend of Rs. 4.50 per equity share.
AI summary

Board of Narayana Hrudayalaya Limited approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Deloitte Haskins & Sells LLP.

The Board recommended a final dividend of Rs. 4.50 per share for FY2026, subject to shareholder approval at the AGM on August 14, 2026; record date is July 17, 2026.

The Board seeks shareholder approval by special resolution to issue debt securities including NCDs up to Rs. 1,500 crores in a financial year on a private placement basis.

The Board proposed re-appointment of Ms. Terri Smith Bresenham (DIN: 09111500) as Independent Director for a second five-year term from August 5, 2026 to August 4, 2031, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
22 May 2026board outcome
Capex, Dividend / buy-back, Management change, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange, the financial results for the quarter and year ended March 31, 2026.
AI summary

Narayana Hrudayalaya Limited filed the outcome of its board meeting held on May 22, 2026, approving audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with an unmodified audit opinion from Deloitte Haskins & Sells LLP.

The board recommended a final dividend of Rs. 4.50 per share for FY2026, subject to shareholder approval at the AGM, with July 17, 2026 fixed as the record date.

The 26th AGM is scheduled for August 14, 2026 via video conferencing/OAVM.

The board approved seeking shareholder special resolution to issue debt securities including NCDs up to Rs. 1,500 crores in a financial year on a private placement basis.

The board approved re-appointment of Ms. Terri Smith Bresenham (DIN: 09111500) as Independent Director for a second five-year term from August 5, 2026 to August 4, 2031, subject to shareholder approval.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Feb 2026transcript
Acquisition, Guidance, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings Call of the Company held on Tuesday, February 17, 2026
AI summary

Narayana Hrudayalaya filed the transcript of its Q3 FY26 earnings call held on February 17, 2026, for the quarter ended December 31, 2025, and said it is also on the company website.

Management (Venkatesh R.) said India realizations improved from transformation and payor mix initiatives, with volumes and occupancy intact, and that the company cannot give specific margin guidance but aims to maintain recent margins barring unknown short-term impacts.

Management (Viren Shetty, Dr. Emmanuel Rupert) said the insurance and clinics business is still in a building stage, breakeven timing is too early to say, and margin dilution will continue as investment continues.

Management said the northern cluster was softer due to receivable problems with some scheme payors, drug reimbursement caps, planned volume reduction in schemes, and new competition.

Management said Bangalore growth reflected higher realizations from robotic cardiac surgery and payor mix work, and noted no timeline for Mumbai licensing changes and no details yet on a new North-focused subsidiary.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026presentation
Acquisition, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya filed its investor presentation for the quarter ended December 31, 2025 (Q3 FY26), with a cover letter dated February 13, 2026.

Consolidated operating revenue was ₹21,512 Mn in Q3 FY26, up 61.2% YoY and 30.9% QoQ; the UK numbers are consolidated from November 6, 2025, the acquisition's effective date.

Consolidated EBITDA was ₹3,904 Mn (18.2% margin) and consolidated PAT was ₹1,281 Mn (6.0% margin).

Net debt (total borrowings less cash, bank balances and investments) was ₹22,321 Mn as on December 31, 2025, a net debt to equity ratio of 0.53.

Management highlighted 244 robotic cardiac surgeries at Narayana Institute of Cardiac Sciences, Bangalore (35% increase QoQ), and the first heart transplant at Narayana Multi-specialty Hospital, Ahmedabad in December 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Acquisition, Legal, Results
Narayana Hrudayalaya Ltd. has informed the Exchange regarding the approval of the Unaudited Standalone and Consolidated Financial Results for the quarter and period ended December 31, 2025 at its Board meeting held on February 13, 2026.
AI summary

Narayana Hrudayalaya Limited's board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 on February 13, 2026.

Standalone revenue from operations for Q3 FY26 was ₹9,687.81 million, against ₹8,650.43 million a year earlier; standalone net profit was ₹757.37 million, against ₹792.23 million.

Q3 standalone profit before tax was ₹992.62 million after an exceptional item of ₹452.76 million for increased gratuity and leave liabilities from the new Labour Codes.

For nine months ended December 31, 2025, standalone revenue from operations was ₹29,310.91 million and net profit was ₹3,009.88 million.

Basic EPS for the quarter was ₹3.73, against ₹3.90 a year earlier.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Feb 2026board outcome
Acquisition, Legal, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange, the unaudited Standalone and Consolidated financial results for the quarter and period ended December 31, 2025 approved by the Board at its meeting held on February 13, 2026.
AI summary

Board approved unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (board meeting held February 13, 2026).

Standalone Q3 FY26 revenue from operations was ₹9,687.81 million, against ₹8,650.43 million a year earlier; net profit was ₹757.37 million, against ₹792.23 million, after an exceptional item of ₹452.76 million for increased gratuity and leave liabilities under the Labour Codes.

Standalone nine-month revenue from operations was ₹29,310.91 million (₹26,710.95 million a year earlier); nine-month net profit was ₹3,009.88 million (₹2,711.66 million a year earlier).

Basic EPS for the quarter was ₹3.73 (₹3.90 a year earlier), with a face value of ₹10 per share.

The company also reported progress on the merger of subsidiary Meridian Medical Research & Hospital Ltd. (NCLT petition filed January 23, 2026) and a demerger scheme for NH Integrated Care Private Limited (filed with NCLT December 17, 2025), and the incorporation of wholly owned subsidiary Narayana Healthcare North Private Limited on January 16, 2026.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
19 Jan 2026credit rating
Acquisition, Capex, Rating
Narayana Hrudayalaya Ltd. has informed the Exchange about revision in Credit Rating under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
AI summary

Narayana Hrudayalaya Limited filed intimation under Regulation 30 of SEBI LODR on credit rating revision by ICRA Limited, following an earlier intimation dated January 13, 2026.

ICRA reaffirmed ratings at [ICRA]AA (Stable) for long-term instruments, [ICRA]AA (Stable)/[ICRA]A1+ for cash credit and working capital, [ICRA]A1+ for unallocated limits, and [ICRA]AA (Stable) for NCDs; total rated amount is Rs. 5,195 crore, unchanged.

ICRA cited H1 FY2026 revenue growth of 15.0% YoY and operating profit margin of 23.5%, and expects debt metrics to moderate near term due to planned capex of Rs. 700-800 crore in FY2026 and Rs. 1,400-1,450 crore in FY2027 and the Rs. 2,200 crore acquisition of Practice Plus Group Hospitals Limited (UK).

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
16 Jan 2026acquisition
Acquisition, Capex
Narayana Hrudayalaya Ltd. has informed the Exchange about Incorporation of a Wholly Owned Subsidiary (WOS)
AI summary

Narayana Hrudayalaya Limited intimated the incorporation of a wholly owned subsidiary, Narayana Healthcare North Private Limited, on January 16, 2026.

The subsidiary has authorised capital of Rs. 10,00,000 and paid-up capital of Rs. 5,00,000; it is yet to commence business.

The company subscribed to 50,000 equity shares of Rs. 10 each, aggregating Rs. 5,00,000, for 100% of the share capital in cash.

The subsidiary will run hospitals and provide healthcare services in health and wellness management, to give a dedicated entity for the company's presence in the Northern region.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
13 Jan 2026credit rating
Rating
Narayana Hrudayalaya Ltd. has informed the Exchange about Credit Rating
AI summary

Narayana Hrudayalaya Limited filed intimation under Regulation 30 of the SEBI LODR Regulations on credit ratings assigned by ICRA Limited, dated January 12, 2026.

ICRA reaffirmed [ICRA]AA (Stable) on long-term bank facilities including term loan of Rs. 1,912.00 crore and cash credit of Rs. 100.00 crore, with short-term non-fund based facilities of Rs. 45.00 crore rated [ICRA]A1+.

Total bank facilities rated are Rs. 3,895.00 crore, and non-convertible debentures rated [ICRA]AA (Stable) total Rs. 1,300.00 crore, including Rs. 500.00 crore proposed debentures.

All ratings were reaffirmed with a Stable outlook; ICRA states the ratings will be due for surveillance within one year.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Dec 2025scheme
Acquisition, Legal
Narayana Hrudayalaya Ltd. has informed the Exchange about Approval of the Scheme of Arrangement between NH Integrated Care Private Limited ( Demerged Company/NHIC ), Narayana Hrudayalaya Limited ( Resulting Company/NHL ) and their respectiv
AI summary

Narayana Hrudayalaya Limited's board approved, on December 12, 2025, a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 with NH Integrated Care Private Limited and their shareholders and creditors.

The Scheme provides for demerger of the Clinical Services undertaking (10 clinics in Bengaluru) from NH Integrated Care Private Limited into Narayana Hrudayalaya Limited on a going-concern basis, with an appointed date of April 1, 2025.

The Clinical Services undertaking's turnover for FY ended March 31, 2025 was Rs. 39.94 crore, 1.11% of the Resulting Company's standalone turnover for the same year.

No cash consideration or share issuance is involved, as NH Integrated Care Private Limited is a wholly owned subsidiary of Narayana Hrudayalaya Limited.

The Scheme is subject to NCLT approval, other regulatory approvals, and shareholder and creditor approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
12 Dec 2025board outcome
Acquisition, Legal
Narayana Hrudayalaya Ltd. has informed the Exchange regarding Board meeting held on December 12, 2025 regarding Approval of the Scheme of Arrangement between NH Integrated Care Private Limited( Demerged Company/NHIC ), Narayana Hrudayalaya
AI summary

Narayana Hrudayalaya Limited's board approved, on December 12, 2025, a Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013 with its wholly owned subsidiary NH Integrated Care Private Limited and their shareholders and creditors.

The Scheme provides for demerger of the Clinical Services undertaking (10 clinics in Bengaluru) from NH Integrated Care into Narayana Hrudayalaya Limited on a going-concern basis, with an appointed date of April 1, 2025.

The Clinical Services undertaking had turnover of Rs. 39.94 crore for the year ended March 31, 2025, which the filing states is 1.11% of the Resulting Company's standalone turnover for the same year.

No cash consideration or share issuance is involved, and no new listing is required; the Scheme is subject to NCLT approval, other regulatory approvals, and shareholder and creditor approvals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Nov 2025transcript
Guidance, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings Call of the Company held on Monday, November 17 2025
AI summary

Narayana Hrudayalaya filed the transcript of its Q2 FY26 earnings call held on November 17, 2025, for the quarter and half year ended September 30, 2025.

Dr. Anesh Shetty said insurance product uptake in Cayman is strong with most large employers moved or considering moving, and that a steady-state view on market share is expected in about 2-4 quarters; he estimated the Cayman insurance market at roughly USD 300-350 million including government insurance.

Dr. Anesh Shetty said Cayman hospital margins run about 43-44% each quarter, and that Camana Bay hospital revenue rose from USD 25 million to USD 40 million with discharges up about 50%, with a couple more quarters of growth expected.

R. Venkatesh said the Mumbai hospital had a slightly negative single-digit EBITDA in the quarter, with improved performance in October and a hoped-for positive Q3.

R. Venkatesh said India EBITDA growth came from higher bed realization and payer-mix optimisation despite flat volumes, and Dr. Rupert said 97 robotic cardiac surgeries were done in September and close to 200 in the quarter.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Nov 2025board outcome
Acquisition, Dividend / buy-back, Legal, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange, the financial results for the period ended September 30, 2025.
AI summary

Narayana Hrudayalaya Limited filed the outcome of its board meeting held on November 14, 2025, approving unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Standalone revenue from operations for the quarter ended September 30, 2025 was ₹10,191.69 million, against ₹9,431.41 million in the June 2025 quarter; standalone net profit for the quarter was ₹1,378.80 million (₹873.71 million in June 2025 quarter).

Standalone revenue from operations for the six months ended September 30, 2025 was ₹19,623.10 million, against ₹18,060.52 million for the six months ended September 30, 2024; standalone net profit for the six months was ₹2,252.51 million (₹1,919.43 million in the prior-year period).

A final dividend of ₹4.50 per equity share (₹919.62 million in total) for the year ended March 31, 2025 was approved at the AGM on August 29, 2025 and paid during the quarter.

The Scheme of Arrangement for merger of subsidiary Meridian Medical Research & Hospital Ltd. was filed with the National Company Law Tribunal, Bengaluru Bench on September 27, 2025, with the next hearing to be scheduled in due course.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Nov 2025presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya Limited filed its investor presentation for the quarter and half year ended September 30, 2025 (Earnings Update Q2 FY26).

Consolidated operating revenues were ₹ 16,438 Mn in Q2 FY26, up 20.3% YoY and 9.1% QoQ.

Consolidated EBITDA was ₹ 4,265 Mn at a margin of 25.9%, and consolidated PAT was ₹ 2,583 Mn at a margin of 15.7%.

Consolidated net debt to equity ratio was 0.06, with net debt of ₹ 2,466 Mn as on September 30, 2025.

Management highlighted a record number of robotic and minimally invasive cardiac procedures at Narayana Institute of Cardiac Sciences, Bangalore, and the commissioning of a 256 slice CT scan at Narayana Superspeciality Hospital, Howrah.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
14 Nov 2025board outcome
Acquisition, Dividend / buy-back, Legal, Results
Narayana Hrudayalaya Ltd. has informed the Exchange regarding the approval of the unaudited financial results for the quarter and half year ended September 30, 2025 at the Board meeting held on November 14, 2025.
AI summary

Board of Narayana Hrudayalaya Limited approved unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 at a meeting held November 14, 2025 (3:30 PM to 6:10 PM IST); the statutory auditor issued a limited review report with no matters to report.

Standalone revenue from operations for the quarter ended September 30, 2025 was ₹10,191.69 million, against ₹9,431.41 million in the June 2025 quarter; standalone net profit for the quarter was ₹1,378.80 million versus ₹873.71 million in the preceding quarter.

Standalone revenue from operations for the six months ended September 30, 2025 was ₹19,623.10 million, against ₹18,060.52 million a year earlier; standalone net profit for the half year was ₹2,252.51 million, compared with ₹1,919.43 million for the six months ended September 30, 2024.

A final dividend of ₹4.50 per equity share (₹919.62 million in total) for FY2024-25, approved at the AGM on August 29, 2025, was paid during the quarter.

The Scheme of Arrangement for merger of subsidiary Meridian Medical Research & Hospital Ltd. was filed with the NCLT Bengaluru Bench on September 27, 2025; BSE and NSE had issued No Observation Letters in June 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
07 Nov 2025transcript
Acquisition, Dividend / buy-back, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of Investor s Call -Acquisition of UK-based Practice Plus Group Hospitals Limited
AI summary

Narayana Hrudayalaya Limited filed the transcript of its investor call held on November 03, 2025 on the acquisition of UK-based Practice Plus Group Hospitals Limited.

Management said the company is acquiring 100% of the Hospitals division (the Secondary Care division) of the three-division company on a debt-free basis, with the seller handling existing term loan repayment and only regular creditors and lease liabilities being taken over.

Management said Practice Plus was chosen for its size, payor mix and a senior management team that will stay on after the deal.

CFO Sandhya J said the post-IFRS EBITDA for FY25 is GBP 29 million, versus GBP 20 million earlier reported on a pre-IFRS basis, and that a revised deck will be uploaded.

Management said figures in the public annual report differ from the carved-out financials in the deck because of cross-charges and other business data, and that the inter-company dividend arrangement has not yet been decided.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Nov 2025presentation
Acquisition, Capex, Guidance
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya filed a revised investor presentation on its acquisition of UK-based Practice Plus Group Hospitals Limited, following its October 31, 2025 disclosure.

The company acquired 100% of Practice Plus Group Hospitals Limited, described as the 5th largest private healthcare network in the UK and the 4th largest NHS healthcare service provider in the UK.

The acquisition is for about GBP 183 million, implying a 9.2x FY25E EV/EBITDA multiple on currently operational centers, and is funded partly by about GBP 150 million of long-term debt with a 7-year tenor.

Per the presentation, no pre-closing regulatory approvals are required and transaction closing is expected within the next few days.

The target's FY25E revenue is GBP 250 million, against GBP 229 million in FY24, with revenue growing at a 12% CAGR over five years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025presentation
Acquisition, Capex, Guidance
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya filed an investor presentation on its acquisition of UK-based Practice Plus Group Hospitals Limited, further to a disclosure made on October 30, 2025.

The target is acquired 100% for about GBP 183 million, implying 9.2x FY25E EV/EBITDA on currently operational centers (adjusted for cash retained in the entity).

About GBP 150 million is to be financed through long-term debt with a 7-year tenor; no pre-closing regulatory approvals are required and closing is expected within the next few days.

The target had FY24 revenue of GBP 229 million and FY25E revenue of GBP 250 million, with revenue growing at a 12% CAGR over the last five years, and 93% of its revenue is from NHS.

Management describes the deal as a low-risk, value-accretive entry into a mature UK market with a shift toward day-care procedures and asset-light operations.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
31 Oct 2025presentation
Acquisition, Capex
Narayana Hrudayalaya Ltd. has informed the Exchange about an investor presentation on the acquisition of UK-based Practice Plus Group Hospitals Limited
AI summary

Narayana Hrudayalaya filed an investor presentation on its acquisition of UK-based Practice Plus Group Hospitals Limited, further to a disclosure made on October 30, 2025.

The target is acquired 100% and is described as the 5th largest private healthcare network in the UK and the 4th largest NHS healthcare service provider in the UK.

Acquisition consideration is about GBP 183 million, implying a 9.2x FY25E EV/EBITDA multiple on currently operational centers, financed by about GBP 150 million of long-term debt with a 7-year tenor.

Management said no pre-closing regulatory approvals are required and transaction closing is expected within the next few days.

Target revenue was GBP 229 million in FY24 and is estimated at GBP 250 million in FY25E, with revenue growing at a 12% CAGR over the last five years.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
30 Oct 2025acquisition
Acquisition
Narayana Hrudayalaya Ltd. has informed the Exchange about the Acquisition of Practice Plus Group Hospitals Limited in the United Kingdom
AI summary

Narayana Hrudayalaya Limited disclosed under Regulation 30 that its step-down arrangement, Health City Cayman Islands Limited via Narayana Hrudayalaya UK Ltd, has signed an agreement dated October 30, 2025 to acquire 100% equity shares of Practice Plus Group Hospitals Limited, a UK hospital operator, subject to closing conditions.

Total consideration is GBP 188.78 million in cash, with closing due within 6 business days of the agreement unless otherwise agreed; no governmental or regulatory approvals are stated as required.

The target had turnover of GBP 229 million in FY24 and an estimated GBP 250 million in FY25 (years ending September), with 330 beds, about 2,500 FTEs and 7 hospitals plus other centers.

The company said the acquisition will build on Narayana Health's international presence following its Caribbean expansion through Health City Cayman Islands.

The acquisition is not a related party transaction, and no promoter or group company has an interest in the target.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
11 Aug 2025transcript
Capex, Guidance, Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Transcript of the Earnings Call of the Company held on Monday, August 04, 2025
AI summary

Narayana Hrudayalaya filed the transcript of its Q1 FY26 earnings call held on August 4, 2025, for the quarter ended June 30, 2025; the transcript is also on the company website.

Management said Cayman hospital patient volumes fell quarter on quarter due to early-stage volatility in the new hospital, and expects stabilisation over two to three quarters.

Management said Integrated Care, which began formal external sales on January 1, 2025, is loss-making in its first one to two quarters and is expected to approach breakeven by the end of the year or Q1 of next year.

Management said it is too early to give a Cayman combined EBITDA margin guidance, but intends healthy absolute earnings growth.

Management said new hospitals planned for 2027-2028 will have breakeven in line with market and realisations at a discount to current market prices in those geographies.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
03 Aug 2025presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Narayana Hrudayalaya Limited filed a revised investor presentation for the quarter ended June 30, 2025 (Q1 FY26), dated August 03, 2025.

Consolidated operating revenue of ₹15,073 Mn in Q1 FY26, up 15.4% YoY and 2.2% QoQ.

Consolidated EBITDA of ₹3,607 Mn at a 23.9% margin; consolidated PAT of ₹1,961 Mn at a 13.0% margin.

Consolidated net debt to equity ratio of 0.09 as on June 30, 2025, with net debt of ₹3,430 Mn.

Management highlighted clinical milestones, including first-of-its-kind procedures at Raipur and HSR (Bangalore) hospitals.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025board outcome
Acquisition, Legal, Results
Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.
AI summary

Board meeting held August 1, 2025 approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Standalone revenue from operations for the quarter ended June 30, 2025 was Rs 9,431.41 million, against Rs 8,717.61 million a year earlier; standalone net profit was Rs 869.28 million, against Rs 839.33 million in the year-ago quarter.

The Board resolved to seek shareholder approval by special resolution for issuing debt securities, including NCDs, up to Rs 2,500 crores (revised limit) in a financial year, on a private placement basis.

The Board also noted that the stock exchanges issued "No Observation Letters" on the merger scheme with Meridian Medical Research & Hospital Ltd. on June 23 and June 24, 2025, and the company is in the process of filing the scheme with the National Company Law Tribunal.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025presentation
Results
Narayana Hrudayalaya Ltd. has informed the Exchange about Investor Presentation
AI summary

Investor presentation for the quarter ended June 30, 2025 (Q1 FY26), filed by Narayana Health (NH).

Consolidated operating revenue of ₹15,073 Mn in Q1 FY26, up 15.4% YoY and 2.2% QoQ.

Consolidated EBITDA of ₹3,607 Mn at a margin of 23.9%; consolidated PAT of ₹1,961 Mn at a margin of 13.0%.

Consolidated net debt to equity ratio of 0.09, with total borrowings less cash, bank balances and investments of ₹3,430 Mn as on June 30, 2025.

Network of 40 healthcare facilities with 5,563 operational beds as on June 30, 2025.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
01 Aug 2025board outcome
Acquisition, Capex, Legal, Results
Narayana Hrudayalaya Ltd. has submitted to the Exchange regarding approval of the unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025.
AI summary

Board of Narayana Hrudayalaya Limited approved unaudited standalone and consolidated financial results for the quarter ended June 30, 2025 on August 01, 2025, with a limited review report from Deloitte Haskins & Sells LLP.

Standalone revenue from operations for Q1 FY26 was Rs 9,431.41 million, against Rs 8,717.61 million in the year-ago quarter (June 30, 2024) and Rs 9,190.27 million in the March 2025 quarter.

Standalone net profit for the quarter was Rs 869.28 million, against Rs 839.33 million in the year-ago quarter; basic and diluted EPS were Rs 4.30 each (not annualised).

The Board also approved seeking shareholder approval by special resolution to issue debt securities, including NCDs, up to Rs 2,500 crores (revised limit) in a financial year, on a private placement basis.

The Scheme of Arrangement for merger of subsidiary Meridian Medical Research & Hospital Ltd. has received No Observation Letters from BSE (June 23, 2025) and NSE (June 24, 2025); the company is to file the Scheme with the National Company Law Tribunal in due course.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
25 Jun 2025scheme
Acquisition, Legal
Narayana Hrudayalaya Ltd. has informed the Exchange about Scheme of Arrangement - Receipt of Observation Letter indicating "No Objection" from National Stock Exchange of India (NSE) in relation to Scheme of Arrangement between Meridian Medi
AI summary

Narayana Hrudayalaya Limited intimated receipt of Observation Letters on the draft Scheme of Arrangement between its subsidiary Meridian Medical Research & Hospital Ltd (transferor) and the company (transferee), under Sections 230-232 of the Companies Act, 2013.

BSE issued an observation letter with "no adverse observations" on June 23, 2025; NSE issued one indicating "no objection" on June 24, 2025.

The NSE letter sets out SEBI's comments on the draft scheme, including disclosure of pending proceedings, valuation and financial information, and shareholder classification in the explanatory statement.

The scheme remains subject to other statutory and regulatory approvals, including from the National Company Law Tribunal and the shareholders and creditors of the entities.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy
24 Jun 2025scheme
Acquisition, Legal
Narayana Hrudayalaya Ltd. has informed the Exchange about Scheme of Arrangement - Receipt of Observation Letters with "No Adverse Observations" from BSE Limited in relation to Scheme of Arrangement between Meridian Medical Research & Hospit
AI summary

Narayana Hrudayalaya Limited intimated receipt of an Observation Letter from BSE Limited dated June 23, 2025, stating "No Adverse Observation" on the proposed Scheme of Arrangement between its subsidiary Meridian Medical Research & Hospital Ltd (transferor company) and the company (transferee company).

The Board had approved the scheme earlier, as intimated in the letter dated November 29, 2024.

The scheme remains subject to other statutory and regulatory approvals, including from the National Company Law Tribunal and approvals from shareholders and creditors.

Written by an AI model (claude-haiku-5-5) from the filing's first pages; it can be wrong - the filing is the source.

NSE copy

The list of announcements the National Stock Exchange publishes for the company; each link opens the exchange's own copy. Ask Sensei searches these filings when a question names the company.

Ask Sensei

Ask Sensei

Ask about any NIFTY 500 company in plain words. The answer comes from its own filings, with the page behind every point.

For example:

See a sample answer

Start free Sign in